期刊
GUT
卷 67, 期 12, 页码 2204-2212出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2017-315846
关键词
-
资金
- US National Institutes of Health [R01 DK113592, U01 AA024206]
- UK Medical Research Council [MR/K10019494/1]
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) [UO1 AA018663]
- National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University
- CR UK Newcastle Experimental Cancer Medicine Center [C9380/A18084]
- CR UK [C18342/A23390]
- Bobby Robson Foundation
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK113592] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA018663, U01AA024206] Funding Source: NIH RePORTER
With the growing number of novel therapeutic approaches for liver diseases, significant research efforts have been devoted to the development of liquid biopsy tools for precision medicine. This can be defined as non-invasive reliable biomarkers that can supplement and eventually replace the invasive liver biopsy for diagnosis, disease stratification and monitoring of response to therapeutic interventions. Similarly, detection of liver cancer at an earlier stage of the disease, potentially susceptible to curative resection, can be critical to improve patient survival. Circulating extracellular vesicles, nucleic acids (DNA and RNA) and tumour cells have emerged as attractive liquid biopsy candidates because they fulfil many of the key characteristics of an ideal biomarker. In this review, we summarise the currently available information regarding these promising and potential transformative tools, as well as the issues still needed to be addressed for adopting various liquid biopsy approaches into clinical practice. These studies may pave the way to the development of a new generation of reliable, mechanism-based disease biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据